Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619940 | 1.00 | GGT1 (0.56) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL94249 | 1.00 | GGT1 (0.56) | GGT1KDM4EMAPTTHRBALOX15 | |
| Hydrochloric Acid SCHEMBL1574244 | 0.98 | GGT1 (0.55) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL5965362 | 0.88 | CPB2 (0.47) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL4996803 | 0.88 | CPB2 (0.47) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL900178 | 0.86 | KDM4E (0.54) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL900182 | 0.86 | KDM4E (0.54) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL17378062 | 0.86 | KDM4E (0.54) | GGT1KDM4EMAPTTHRBALOX15 | |
| Hydrochloric Acid SCHEMBL16993797 | 0.84 | KDM4E (0.52) | GGT1KDM4EMAPTTHRBALOX15 | |
| Lysine SCHEMBL9118672 | 0.83 | GSR (0.61) | GGT1CPB2FOLH1PTGS1SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527880-B2 | Cyanine-based telodendrimers and uses for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | claimed |
| US-20250000811-A1 | TELODENDRIMER NANOCARRIERS FOR MONOMERIC AMPHOTERICIN B DELIVERY | UNIV NEW YORK STATE RES FOUND (US) | 2025-01-02 | — | — | US | claimed |
| US-11649326-B2 | Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-05-16 | — | — | US | claimed |
| US-20230076792-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-09 | — | — | US | claimed |
| CN-115551917-A | Sequential targeting of cross-linked nanotherapeutics for the treatment of brain tumors | 加利福尼亚大学董事会 | 2022-12-30 | — | — | CN | claimed |
| EP-4077477-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-26 | — | — | EP | claimed |
| US-11406714-B2 | Telodendrimers and nanocarriers and methods of using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-08-09 | — | — | US | claimed |
| EP-3347053-B1 | FUNCTIONAL, SEGREGATED, CHARGED TELODENDRIMERS AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | THE RESEARCH FOUNDATION FOR STATE UNIV OF NEW YORK (US) | 2022-05-25 | — | — | EP | claimed |
| US-11219692-B2 | Porphyrin modified telodendrimers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-11 | — | — | US | claimed |
| US-20210346518-A1 | CYANINE-BASED TELODENDRIMERS AND USES FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | claimed |
| WO-2002055111-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB MEDICAL I (US) | 2002-07-18 | — | — | WO | claimed |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-03 | — | — | US | claimed |
| WO-2001097860-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | claimed |
| EP-1068222-A1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION AND FOR IMAGING AND TREATMENT OF CANCER | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1999051628-A1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION AND FOR IMAGING AND TREATMENT OF CANCER | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-14 | — | — | WO | claimed |
| EP-0140556-B1 | A T-DNA DERIVED VECTOR | LUBRIZOL GENETICS INC. (US) | 1992-07-15 | — | — | EP | claimed |
| EP-0140556-A1 | A T-DNA derived vector | LUBRIZOL GENETICS INC. (US) | 1985-05-08 | — | — | EP | claimed |
| US-4425737-A | USING ALPHA-AMYLASE TO IDENTIFY EMBRYO CONTAINING SEED SEGMENTS | AGRIGENETICS RESEARCH ASSOCIATES LIMITED (US) | 1984-01-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346518-A1 | CYANINE-BASED TELODENDRIMERS AND USES FOR TREATING CANCER | TYR, LGALS3, ABL1 | GGT1 1456/4885KDM4E 1460/4885MAPT 692/4885 |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | VEGFA, FLT4, FLT1 | GGT1 2639/4885KDM4E 3470/4885MAPT 4628/4885 |
| US-12527880-B2 | Cyanine-based telodendrimers and uses for treating cancer | TUBB1, CA13, YWHAZ | GGT1 448/4885KDM4E 1029/4885MAPT 226/4885 |
| US-20230076792-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | TIE1, CA12, CA13 | GGT1 396/4885KDM4E 2477/4885MAPT 86/4885 |
| US-11406714-B2 | Telodendrimers and nanocarriers and methods of using same | TTI2, MTCL3, HTT | GGT1 2343/4885KDM4E 3380/4885MAPT 13/4885 |
| US-11649326-B2 | Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same | TSPO, TBCA, TTI2 | GGT1 1890/4885KDM4E 2282/4885MAPT 87/4885 |
| US-11219692-B2 | Porphyrin modified telodendrimers | CETP, NR1H4, ABCB4 | GGT1 869/4885KDM4E 3088/4885MAPT 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.